Adaptimmune Therapeutics plc (ADAP) |
|
4.12 -0.17 (-3.96%)
|
04-18 16:00 |
|
Open: |
4.31 |
Pre. Close: |
4.29 |
|
High:
|
4.34 |
Low:
|
3.935 |
|
Volume:
|
302,059 |
Market Cap:
|
431M |
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
4.352 - 4.376 |
4.376 - 4.396 |
|
Low:
|
3.861 - 3.892 |
3.892 - 3.918 |
|
Close:
|
4.071 - 4.12 |
4.12 - 4.16 |
|
|
|
Technical analysis |
as of: 2019-04-18 4:34:04 PM |
|
Overall:
|
  |
| Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected. |
| Target: |
Six months: 5.55 One year: 6.42 |
| Support: |
Support1: 3.55 Support2: 2.95 |
| Resistance: |
Resistance1: 4.76 Resistance2: 5.50 |
| Pivot: |
4.57  |
| Moving Average: |
MA(5): 4.25 MA(20): 4.39
MA(100): 4.78 MA(250): 8.39 |
| MACD: |
MACD(12,26): -0.01 Signal(9): 0.04 |
| Stochastic oscillator: |
%K(14,3): 22.00 %D(3): 27.88 |
| RSI: |
RSI(14): 43.65 |
| 52-week: |
High: 14.63 Low: 3.55 Change(%): -66.9 |
| Average Vol(K): |
3-Month: 26070 10-Days: 17822 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.ADAP has closed above bottom band by 19.5%. Bollinger Bands are 8.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Mon, 28 Jan 2019 16:51:24 Z
Adaptimmune Therapeutics PLC (ADAP) Upgraded to Buy: Here's What You Should Know
Tue, 08 Jan 2019 23:42:23 Z
Radius Exceeds 2018 Financial Guidance, Provides Updates
Tue, 08 Jan 2019 16:42:36 Z
Alnylam (ALNY) Reports Preliminary Onpattro Revenues for Q4
Wed, 12 Dec 2018 21:26:46 Z
Health Care Sector Update for 12/12/2018: NBIX, TLGT, ADAP
Tue, 06 Nov 2018 18:13:24 Z
European ADRs Edge Lower as Pharma Stocks See Mixed Gains
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
|
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
|
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Click here to get more fundamental analysis.
|
|
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
104.71 |
| Shares Float (M) |
43.24 |
|
% Held by Insiders
|
0.22 |
|
% Held by Institutions
|
73.00 |
|
Shares Short (K)
|
3730 |
|
Shares Short P. Month (K)
|
|
Stock Financials |
|
EPS
|
-0.981 |
|
EPS Est. Current Year
|
-0.990 |
|
EPS Est. Next Year
|
|
|
EPS Est. Next Quarter
|
-0.250 |
|
Forward EPS
|
-1.310 |
|
Book Value (p.s.)
|
2.360 |
|
PEG Ratio
|
-3.62 |
|
Profit Margin
|
-160.51 |
|
Operating Margin
|
-138.42 |
|
Return on Assets (ttm)
|
-18.5 |
|
Return on Equity (ttm)
|
-42.5 |
|
Qtrly Rev. Growth
|
-65.4 |
|
Gross Profit (p.s.)
|
-0.370 |
|
Sales Per Share
|
|
|
EBITDA (p.s.)
|
-0.712 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-104.39 |
|
Levered Free Cash Flow (M)
|
-86.09 |
Stock Valuations |
|
P/E
|
-4.20 |
|
P/E Growth Ratio
|
-0.04 |
|
P/BV
|
1.75 |
|
P/S
|
707221568.00 |
|
P/CF
|
-4.13 |
Dividends & Splits |
|
Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
2018-03-30 |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Forward Dividend
|
|
|
Last Split Date
|
|
|
Last Split Ratio
|
-1e+010 |
|
7 Binary Options
|
|
Your Ad Here
|
|
